Phase I Dose Escalation Study Using Pyrvinium Pamoate Targeting HuR in Pancreatic Ductal Adenocarcinoma
Summary
The purpose of this phase I study is to evaluate the safety and tolerability of pyrvinium pamoate in patients with pancreatic cancer.
General Information
NCT#: NCT05055323
Study ID: 20F.041
Trial Phase: Phase I
Trial Sponsor: Thomas Jefferson University
Therapies Used in This Trial: Pyrvinium Pamoate